OSAKA, Japan and CAMBRIDGE, Massachusetts, November 8, 2023 ā Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved FRUZAQLAā¢ (fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF …
FBI Reform - fbireform.comFBI Reform - fbireform.com - The News And Times